Cancer Research and Treatment

Julio Allo

1 Article

Frequency and Outcome of Neuroleptic Rotation in the Management of Delirium in Patients with Advanced Cancer: Seong Hoon Shin, David Hui, Gary Chisholm, Jung Hun Kang, Julio Allo, Janet Williams, Eduardo Bruera; Cancer Res Treat. 2015;47(3):399-405. Published online November 24, 2014; DOI: https://doi.org/10.4143/crt.2013.229

Purpose
The response to haloperidol as a first-line neuroleptic and the pattern of neuroleptic rotation after haloperidol failure have not been well defined in palliative care. The purpose of this study was to determine the efficacy of haloperidol as a first-line neuroleptic and the predictors associated with the need to rotate to a second neuroleptic. Materials and Methods We conducted a retrospective review of the charts of advanced cancer patients admitted to our acute palliative care unit between January 2012 and March 2013. Inclusion criteria were a diagnosis of delirium and first-line treatment with haloperidol. Results Among 167 patients with delirium, 128 (77%) received only haloperidol and 39 (23%) received a second neuroleptic. Ninety-one patients (71%) who received haloperidol alone improved and were discharged alive. The median initial haloperidol dose was 5 mg (interquartile ranges [IQR], 3 to 7 mg) and the median duration was 5 days (IQR, 3 to 7 days). The median final haloperidol dose was 6 mg (IQR, 5 to 7 mg). A lack of treatment efficacy was the most common reason for neuroleptic rotation (87%). Significant factors associated with neuroleptic rotation were inpatient mortality (59% vs. 29%, p=0.001), and being Caucasian (87% vs. 62%, p=0.014). Chlorpromazine was administered to 37 patients (95%) who were not treated successfully by haloperidol. The median initial chlorpromazine dose was 150 mg (IQR, 100 to 150 mg) and the median duration was 3 days (IQR, 2 to 6 days). Thirteen patients (33%) showed reduced symptoms after the second neuroleptic. Conclusion Neuroleptic rotation from haloperidol was only required in 23% of patients with delirium and was associated with inpatient mortality and white race.

Citations

Citations to this article as recorded by

Naming racism as a root cause of inequities in palliative care research: a scoping review
Kavita Algu, Joshua Wales, Michael Anderson, Mariam Omilabu, Thandi Briggs, Allison M. Kurahashi
BMC Palliative Care.2024;[Epub] CrossRef
Management of Physical Symptoms in Patients with Advanced Cancer during the Last Weeks and Days of Life
Ahsan Azhar, David Hui
Cancer Research and Treatment.2022; 54(3): 661. CrossRef
Chlorpromazine as Treatment for Refractory Agitation Associated with Pediatric Delirium
Shin Young Kim, Shari Simone, Omayma A. Kishk, Ana Lia Graciano, Hyunuk Seung, Sarah Edwards
The Journal of Pediatric Pharmacology and Therapeutics.2022; 27(8): 725. CrossRef
Pharmacological and non-pharmacological treatment of delirium in an oncological hospital service: an integrative review
Luciana Aparecida Vieira Louro, João Francisco Possari, Antônio Fernandes Costa Lima
Revista Brasileira de Enfermagem.2021;[Epub] CrossRef
Neuroleptic strategies for terminal agitation in patients with cancer and delirium at an acute palliative care unit: a single-centre, double-blind, parallel-group, randomised trial
David Hui, Allison De La Rosa, Annie Wilson, Thuc Nguyen, Jimin Wu, Marvin Delgado-Guay, Ahsan Azhar, Joseph Arthur, Daniel Epner, Ali Haider, Maxine De La Cruz, Yvonne Heung, Kimberson Tanco, Shalini Dalal, Akhila Reddy, Janet Williams, Sapna Amin, Terri
The Lancet Oncology.2020; 21(7): 989. CrossRef
A Scoping Review to Map Empirical Evidence Regarding Key Domains and Questions in the Clinical Pathway of Delirium in Palliative Care
Peter G. Lawlor, Nicole A. Rutkowski, Alistair R. MacDonald, Mohammed T. Ansari, Lindsey Sikora, Franco Momoli, Salmaan Kanji, David K. Wright, Erin Rosenberg, Annmarie Hosie, Jose L. Pereira, David Meagher, Jill Rice, John Scott, Shirley H. Bush
Journal of Pain and Symptom Management.2019; 57(3): 661. CrossRef
Prevalencia de delirium mediante la escala Memorial Delirium Assessment Scale (MDAS) en pacientes oncológicos avanzados ingresados en una Unidad de Cuidados Paliativos. Factores de riesgo, reversibilidad y tratamiento recibido
Verónica Díaz García, Miriam López Pérez, Yolanda Zuriarrain Reyna
Medicina Paliativa.2018; 25(4): 245. CrossRef
Clinical Assessment and Management of Delirium in the Palliative Care Setting
Shirley Harvey Bush, Sallyanne Tierney, Peter Gerard Lawlor
Drugs.2017; 77(15): 1623. CrossRef
Delirium Management: Diagnosis, Assessment, and Treatment in Palliative Care
Min Seok Seo, Yong Joo Lee
The Korean Journal of Hospice and Palliative Care.2016; 19(3): 201. CrossRef
Neuroleptics in the management of delirium in patients with advanced cancer
David Hui, Rony Dev, Eduardo Bruera
Current Opinion in Supportive & Palliative Care.2016; 10(4): 316. CrossRef
Acute symptomatic complications among patients with advanced cancer admitted to acute palliative care units: A prospective observational study
David Hui, Renata dos Santos, Suresh Reddy, Maria Salete de Angelis Nascimento, Donna S Zhukovsky, Carlos Eduardo Paiva, Shalini Dalal, Everaldo Donizeti Costa, Paul Walker, Heloisa Helena Scapulatempo, Rony Dev, Camila Souza Crovador, Maxine De La Cruz,
Palliative Medicine.2015; 29(9): 826. CrossRef

12,739 View
101 Download
12 Web of Science
11 Crossref

Author index